Find Academic Supervisors

Jozef Madzo, Ph.D., serves as an Assistant Professor in the Genome Regulation and Cell Signaling Program at The Wistar Institute's Ellen and Ronald Caplan Cancer Center. He also holds the position of Scientific Director of the Bioinformatics Facility, which he began leading in July 2024. Dr. Madzo joined The Wistar Institute faculty as part of their strategic expansion of bioinformatics capabilities across advanced biomedical research programs. Dr. Madzo's research focuses on computational biology approaches to cancer research, with particular emphasis on DNA methylation drift during normal aging, disease-driven inflammation, and neoplastic transformation. His lab investigates how epigenetic changes, particularly in DNA methylation patterns, influence cancer development and progression. Notably, his work has shown that cells exhibit changes in DNA methylation patterns during aging, and that diet and calorie restriction can slow down age- or inflammation-related DNA methylation drift. His research suggests cancer cells display similar DNA methylation drift, indicating cancer may represent accelerated aging. Analysis of Dr. Madzo's publication record reveals a strong focus on the intersection of epigenetics, aging, and cancer. His work spans DNA methylation analysis, gut microbiome interactions with host epigenetics, and the role of epigenetic modifications in cancer development. Recent publications demonstrate increasing sophistication in multi-omics approaches, integrating RNAseq, ATACseq, and scRNA-seq data to uncover mechanisms of genetic and epigenetic regulation. Dr. Madzo's laboratory utilizes advanced computational methods including permutation tests, multivariate analysis, and machine learning techniques such as random forest, XGBoost, and stochastic gradient descent. They work extensively with high-dimensional data from public repositories like TCGA, ENCODE, and GEO, applying both existing open-source bioinformatics tools and custom Python and R scripts.

• Computational Biology
• DNA Methylation
• Epigenetics
• +6 more

Dr. Leslie J. Padrnos is an Assistant Professor of Medicine at Mayo Clinic College of Medicine in Phoenix, Arizona, specializing in Hematology and Medical Oncology with particular expertise in nonmalignant hematology. She serves in multiple leadership roles including Chair of the Mayo Arizona Multidisciplinary Bleeding Meeting, Chair of the Non-Malignant Hematology Conference, and Chair of the Coagulation and Thrombosis Board. As Core Faculty for the Hematology Oncology Fellowship program, she plays a significant role in medical education and resident supervision. Dr. Padrnos's research focuses on thrombosis and hemostasis conditions, with particular emphasis on complex thrombotic disorders, cancer-associated thrombosis, and bleeding disorders. Her clinical work integrates comprehensive medical knowledge with psychological management and patient education to optimize individual patient outcomes. She has published extensively on topics including anticoagulation therapy, venous thromboembolism, and hematologic complications of cancer and other conditions. Her recent publications demonstrate significant contributions to the understanding of thrombosis in the context of emerging health challenges including the COVID-19 pandemic, with research on vaccine-related thrombotic events and optimal anticoagulation strategies. Her work spans both clinical research and educational interventions aimed at improving patient outcomes and knowledge. 2024 ASH Ambassador Faculty with Student Interest Group Subcommittee, American Society of Hematology 2023 Medical Educators Institute, American Society of Hematology 2020 Hematology Oncology & Palliative Medicine Teacher of the Year Award 2017 Mayo Clinic Scholar, Seattle Cancer Care Alliance 2016 Clinical Research Training Institute, American Society of Hematology 2016 Chief Hematology Oncology Fellow Dr. Padrnos supervises Internal Medicine residents during their hematology rotations and mentors hematology/oncology fellows through her Core Faculty role. She has developed meaningful clinical programs focused on bleeding disorders and thrombosis management, with particular attention to patient-centered care approaches that incorporate individual goals and values. Her leadership extends to multiple committees including the Pharmacy and Therapeutic Subcommittee and the Scientific and Standardization Committee on Hemostasis and Malignancy with the International Society of Thrombosis and Hemostasis. She leads the Non-Malignant Hematology and Thrombosis Research Group at Mayo Clinic Arizona, focusing on clinical research that bridges the gap between laboratory findings and patient care. Her team investigates optimal management strategies for complex thrombotic conditions and bleeding disorders, with particular attention to cancer-associated thrombosis and anticoagulation selection.

• Hematology
• Oncology
• Thrombosis
• +7 more

Dr. Talha Badar is an Assistant Professor in the Department of Hematology Oncology at Mayo Clinic Comprehensive Cancer Center in Jacksonville, Florida. He serves as a member of the Acute Leukemia/Myelodysplasia Group and specializes in treating various leukemias and myeloid disorders. Dr. Badar holds multiple leadership roles including Membership on the NCCN Acute Lymphoblastic Leukemia Panel, the American Society of Hematology Publication Committee, and the Mayo Clinic Cancer Center Scientific Review Committee. Dr. Badar completed his medical education at Jinnah Medical and Dental College (2006), followed by residencies in Internal Medicine at College of Physicians and Surgeons Pakistan (2009) and Brandon Regional Hospital (2017). He further specialized through fellowships in Medical Oncology at College of Physicians and Surgeons Pakistan (2013), Clinical Leukemia at MD Anderson Cancer Center (2015), and Hematology and Oncology at Medical College of Wisconsin (2020). He is board certified in Internal Medicine, Hematology, and Medical Oncology. 2020 Fellowship - Hematology and Oncology, Medical College of Wisconsin 2017 Residency - Internal Medicine, Brandon Regional Hospital 2015 Fellowship - Clinical Leukemia, University of Texas MD Anderson Cancer Center 2013 Fellowship - Medical Oncology, College of Physicians and Surgeons Pakistan 2009 Residency - Internal Medicine, College of Physicians and Surgeons Pakistan 2006 MBBS, Jinnah Medical and Dental College Dr. Badar's research focuses on understanding molecular mechanisms underlying myeloid disorders and developing innovative treatment strategies. His work particularly emphasizes TP53-mutated myeloid neoplasms, FLT3-ITD mutated acute myeloid leukemia, and optimizing treatment approaches using hypomethylating agents and venetoclax. His extensive publication record demonstrates a strong commitment to translating research findings into improved clinical outcomes for patients with high-risk leukemias. Analysis of Dr. Badar's 15 most recent publications reveals a consistent focus on precision medicine approaches for myeloid malignancies, with particular emphasis on risk stratification of TP53-mutated diseases, treatment sequencing for AML, and real-world outcomes of novel therapeutic approaches. His work frequently involves large multi-institutional collaborations through consortia such as COMMAND, CIBMTR, and ECOG-ACRIN, demonstrating his leadership in the hematology research community. 2019 Outstanding Fellow Research Award, Wisconsin Association of Hematology and Oncology 2017 Best Resident Research Award, HCA West Florida GME Consortium 2017 People's Choice Award, Health Corporation of America West Division 2015 Future Leaders Award for Clinical Research in Hematology, Celgene 2014 Best Abstract Achievement Award, American Society of Hematology Dr. Badar actively mentors through his role as a faculty member at Mayo Clinic and serves on multiple review committees including the Mayo Clinic Cancer Center Scientific Review Committee and the Data Safety Monitoring Committee. His research is supported through his position as an Investigator for the National Cancer Institute and through participation in multiple clinical trials. He maintains active collaborations with national and international research groups, enhancing opportunities for trainees and junior investigators. As a member of the Mayo Clinic Comprehensive Cancer Center's Acute Leukemia/Myelodysplasia Group, Dr. Badar leads research initiatives focused on molecular mechanisms of myeloid disorders. His laboratory work, conducted in collaboration with Mayo Clinic's advanced research facilities, investigates genetic and molecular drivers of treatment resistance in high-risk leukemias, with the goal of developing more effective therapeutic strategies for these challenging conditions.

• Acute leukemia
• Myeloid disorders
• Cellular therapy
• +7 more

Dr. Hussein A. Abbas serves as Assistant Professor in the Department of Leukemia and Department of Genomic Medicine at The University of Texas MD Anderson Cancer Center. He maintains significant academic affiliations including Adjunct Assistant Professor in the Division of Cancer Medicine at the University of Texas School of Biomedical Informatics and Regular Member status in the University of Texas Graduate School of Biomedical Sciences, where he participates in both the Cancer Biology and Immunology Programs. His research program centers on hematologic malignancies, with specialized focus on systemic mastocytosis and acute myeloid leukemia. Dr. Abbas investigates leukemic cell dynamics within the immune microenvironment through integrative analysis of genomic, transcriptomic, and epigenomic data from patient samples. This approach aims to uncover biomarkers predictive of treatment response and identify molecular mechanisms underlying therapy resistance. As a clinician-scientist, Dr. Abbas directly translates research insights into clinical practice for hematologic malignancy patients. His work bridges laboratory discoveries with patient care through MD Anderson's clinical trials infrastructure, contributing to the development of more effective personalized treatment strategies for challenging blood cancers.

• Hematologic Malignancies
• Acute Myeloid Leukemia (AML)
• Systemic Mastocytosis
• +6 more

Mary M. Horowitz is a Professor in the Department of Medicine, Division of Hematology and Oncology at the Medical College of Wisconsin. She serves as Scientific Director Emeritus of the Center for International Blood and Marrow Transplant Research, Deputy Cancer Center Director, and Director of the Data and Coordinating Center for the Blood and Marrow Transplant Clinical Trials Network. Dr. Horowitz is also a member of both the Cancer Center and the Mellowes Center for Genomic Sciences and Precision Medicine at MCW. Dr. Horowitz's research focuses on bone marrow transplantation, hematopoietic stem cell transplantation, and related clinical trials. Her specific areas of interest include: Adult Allografts and Bone Marrow Transplantation Clinical Trials methodology and design Data Collection and Databases for transplant outcomes Donor Selection criteria and optimization Hematopoietic Stem Cell Transplantation techniques Management of Neoplasms and Second Primary cancers Risk Factor analysis for transplant recipients Transplantation, Autologous approaches Her recent publications (2024-2025) demonstrate a continued focus on advancing the field of hematopoietic cell transplantation, with particular emphasis on improving outcomes for elderly patients, developing risk assessment models, and optimizing graft-versus-host disease prophylaxis. Dr. Horowitz has been instrumental in several major clinical trials through the Blood and Marrow Transplant Clinical Trials Network, including studies on alternative donor transplantation, haploidentical bone marrow transplantation for sickle cell disease, and the use of gilteritinib for FLT3-ITD mutated acute myeloid leukemia. Dr. Horowitz has received significant recognition through her leadership roles in major national and international transplant research organizations. Her role as Scientific Director Emeritus of the Center for International Blood and Marrow Transplant Research reflects her substantial contributions to the field. She has also played key roles in numerous multicenter clinical trials that have shaped current practices in bone marrow transplantation. As Deputy Cancer Center Director and Director of the Data and Coordinating Center for the Blood and Marrow Transplant Clinical Trials Network, Dr. Horowitz oversees significant research infrastructure and funding. Her work bridges clinical practice and research, with a strong emphasis on translating evidence into practice to improve patient outcomes in transplantation medicine. Dr. Horowitz leads research initiatives focused on data collection, analysis, and dissemination related to bone marrow and stem cell transplantation. While a specific lab name isn't mentioned in the provided information, her leadership of the Data and Coordinating Center suggests a strong team focused on clinical trial coordination, data management, and statistical analysis for transplantation research.

• Bone Marrow Transplantation
• Hematopoietic Stem Cell Transplantation
• Oncology
• +5 more

Dr. Sameem Abedin is an Associate Professor in the Department of Medicine, Division of Hematology and Oncology at the Medical College of Wisconsin. He serves as Medical Director of the Inpatient Translational Research Unit and previously directed the Adult Early Phase Program in Hematologic Malignancies. Dr. Abedin completed his medical training at Sidney Kimmel Medical College, residency at the University of Pittsburgh, and fellowship in Hematology/Oncology at Northwestern University. Dr. Abedin's research focuses on acute myeloid leukemia therapeutics and graft-versus-host disease management. His laboratory work investigates novel therapeutic approaches for relapsed/refractory AML, including CDK9 inhibitors and antibody-drug conjugates, while his clinical research examines GVHD prophylaxis strategies and transplantation outcomes. His recent publications demonstrate expertise in translating laboratory findings to clinical applications for hematologic malignancy patients. Analysis of Dr. Abedin's 15 most recent publications (2024-2025) reveals a strong focus on therapeutic innovation in AML and GVHD management. His work spans from early-phase clinical trials of novel agents to comparative effectiveness research and practice-changing supportive care strategies. The publications demonstrate methodological diversity including randomized trials, cohort studies, and systematic reviews across high-impact hematology journals. Hobart Amory Hare Medical Honor Society (2008-2009) Foerderer Award for International Study (2009) ASBMT Clinical Research Scholar (2016) CTSI Clinical Research Scholar (2017-2019) Faculty Development Award, Medical College of Wisconsin (2018-2019) Top Patient Experience Award, Froedtert Hospital (2019) Dr. Abedin actively mentors medical students, residents, and fellows, with several mentees presenting at national meetings and publishing in peer-reviewed journals. His research program is supported by multiple industry-sponsored clinical trials where he serves as Principal Investigator, including studies of Lintuzumab-Ac225 for AML and Neihulizumab for GVHD. As Medical Director of the Inpatient Translational Research Unit, he oversees the infrastructure for early-phase clinical trials requiring coordinated inpatient care, facilitating the rapid growth of the institution's clinical trial portfolio.

• Acute Myeloid Leukemia
• Graft-versus-Host Disease
• Hematopoietic Stem Cell Transplantation
• +6 more

Dr. Ehab L. Atallah is a Professor of Medicine in the Department of Hematology and Oncology at the Medical College of Wisconsin, where he has been on faculty since 2007. He currently serves as Associate Director of the Cancer Service Line at Froedtert Hospital and previously held leadership positions as Section Head of Hematological Malignancies and Hematological Malignancies Disease-Oriented Team Lead. Dr. Atallah is a member of both the Cancer Center and Center for Immunology at MCW, with clinical expertise in hematologic malignancies. Dr. Atallah's research focuses on hematologic malignancies with particular emphasis on chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). His work encompasses treatment-free remission strategies in CML, optimizing tyrosine kinase inhibitor therapy, studying TP53-mutated myeloid neoplasms, and developing novel treatment approaches for AML. He frequently investigates real-world treatment patterns and outcomes, with a strong interest in translating research findings into clinical practice. His recent publications demonstrate expertise in both clinical trials and observational studies, with significant contributions to national consortia including the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Analysis of Dr. Atallah's recent publications (2023-2025) reveals a strong focus on precision medicine approaches in hematologic malignancies, with particular attention to molecularly defined subgroups such as TP53-mutated diseases. His work spans multiple therapeutic areas including novel agent development (asciminib), combination therapies (venetoclax-based regimens), and treatment discontinuation strategies. The publications demonstrate a balance between mechanistic investigations and real-world evidence studies, reflecting his commitment to both scientific advancement and practical clinical application. Mentor Award (2017) Faculty Development Award (2016) Outstanding Medical Student Teacher Award (2014, 2016, 2021) Best Doctors in America (2015-2023) Department of Medicine Engstrom Murphy Award for Clinical Contribution (2015) Teacher of the Year Award by Internal Medicine residents (2009) MERIT award, ASCO Cancer Foundation (2007) Dr. Atallah has served as Principal Investigator or Institutional PI for numerous research grants, including the ongoing ASC2ESCALATE trial (Phase II study of Asciminib in second-line CML), ECOG/ACRIN trials for AML and ALL, and a CTSI Traditional Pilot Award investigating RAS pathway activation in AML. He has mentored numerous fellows, residents, and medical students throughout his career, evidenced by multiple teaching awards. His leadership extends to national consortia where he serves as Steering Committee Chair for ASC2ESCALATE, Co-Chair of ECOG-ACRIN Leukemia, and member of the iCMLf Scientific Advisory Board. As Associate Director of the Cancer Service Line at Froedtert Hospital, Dr. Atallah contributes to strategic planning and operational leadership for cancer care delivery. His research program benefits from strong institutional support at the Medical College of Wisconsin Cancer Center, where he has served on multiple committees including the Data Safety Monitoring Committee and Clinical Translational Pilot Grant Committee. His work often involves multi-institutional collaborations through national networks such as ECOG-ACRIN and the Consortium on Myeloid Malignancies and Neoplastic Diseases.

• Hematologic Neoplasms
• Leukemia
• Myelodysplastic Syndromes
• +8 more

Siegfried Janz is a Professor at the Medical College of Wisconsin, affiliated with the Department of Medicine (Division of Hematology and Oncology) and the Cancer Center. His research specializes in multiple myeloma, leveraging molecular oncology, immunotherapy, and genetic studies to advance therapeutic strategies. Dr. Janz investigates tumor microenvironments, drug synergies (e.g., FOXM1/BCL-2 inhibitors), CAR-T therapies, and mouse models of cancer. His recent work identifies prognostic biomarkers through genomic analyses and explores immune evasion mechanisms in myeloma. His publications (2019-2025) predominantly focus on hematologic malignancies, with trends in: Immunotherapy development (bispecific antibodies, CAR-T) Genetic drivers of myeloma progression Preclinical validation of therapeutic targets COVID-19 outcomes in transplant patients

• Multiple Myeloma
• Oncology
• Hematology
• +3 more

Dr. Ina Lee serves as an Assistant Research Physician in the Laboratory of Pathology at the Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health. As a molecular pathologist within the NCI COMPASS program, she provides state-of-the-art clinical sequencing services to advance cancer research through genomic diagnostics. Her academic training includes: M.D. and Ph.D. from the Medical Scientist Training Program at University of Illinois at Chicago School of Medicine Combined pathology residency (AP/CP) and hematopathology fellowship at University of Maryland Medical Center Molecular Genetic Pathology fellowship at University of North Carolina, Chapel Hill Dr. Lee's research centers on genomic features of hematologic malignancies with specialized focus on integrated precision diagnostics for hematolymphoid neoplasms and myeloid neoplasm biology. She actively develops molecular testing frameworks that bridge genomic discoveries with clinical diagnostic applications, emphasizing multidisciplinary approaches to improve cancer detection and monitoring. Her publication record demonstrates consistent contributions across oncology and molecular pathology, with recent work examining chromosomal abnormalities in leukemia progression, posttransplant lymphoma diagnostics, and viral pathogenesis mechanisms. This output reveals a strong trajectory in applying genomic technologies to solve clinical diagnostic challenges in blood cancers. As a physician-scientist, Dr. Lee maintains dual roles in clinical diagnostics and translational research. Her position within the NCI intramural program indicates active participation in federally funded initiatives, particularly through the COMPASS sequencing platform that supports multiple research teams across the Center for Cancer Research. Dr. Lee operates within the Laboratory of Pathology's collaborative ecosystem, leveraging advanced genomic technologies to address diagnostic challenges in hematologic malignancies. Her work exemplifies the NIH's mission to translate molecular discoveries into clinical applications through integrated diagnostic strategies.

• Molecular Pathology
• Hematologic Malignancies
• Genomics
• +3 more

Samuel H. Fantaye, MD, MPH, FACP, DABOM, is an Assistant Professor in the Department of Internal Medicine/Endocrinology at Morehouse School of Medicine. He holds triple board certifications in Internal Medicine, Endocrinology, and Obesity Medicine from the American Board of Internal Medicine. Education: Doctor of Medicine: Addis Ababa University Master of Public Health: University of Gondar Residency (Internal Medicine): WellStar Atlanta Medical Center Fellowship (Endocrinology, Diabetes and Metabolism): Harbor UCLA/City of Hope Cancer Center His research integrates clinical endocrinology with public health, focusing on diabetes complications, obesity, thyroid disorders, and healthcare disparities. Recent work examines pharmacological interventions for diabetes-related kidney disease and sociodemographic factors influencing cancer outcomes. Awards & Honors: Fellow, American College of Physicians (FACP) Certificate of Appreciation for Excellence in Internal Medicine Training (WellStar) USAID/US Embassy Recognition for Health Program Innovation No lab affiliations, student advisories, or grant activities are detailed in available sources.

• Diabetes Pathogenesis
• Cardiovascular Complications
• Obesity and Metabolism
• +3 more

Kate Hyde, PhD, is an Associate Professor in the Department of Biochemistry and Molecular Biology at the University of Nebraska Medical Center (UNMC) College of Medicine. She also serves as Associate Director for Shared Resources at the Fred & Pamela Buffett Cancer Center. Her laboratory investigates molecular mechanisms of acute myeloid leukemia (AML), with emphasis on chromosome 16 inversion (Inv(16))-driven AML and the oncogenic fusion protein CBFβ-SMMHC. Education includes: Bachelors of Arts in Biology from Washington University in St. Louis PhD in Cellular and Molecular Biology from University of Wisconsin-Madison Post-doctoral fellowship at National Human Genome Research Institute, NIH Her research integrates: Leukemia and normal blood development pathways Regulation of gene expression in hematological malignancies Development of targeted therapies using mouse models and drug delivery systems She collaborates extensively, including projects with UNMC College of Pharmacy on polymeric CXCR4 inhibitors. Recent publication trends (15 most recent) focus on: Leukemia stem cell persistence mechanisms in bone marrow CXCR4-targeted drug delivery systems Epigenetic regulators (HDAC1) and metabolic dependencies in AML Novel therapeutics like liposomal miR-497-5p/venetoclax combinations RUNX1/CBFβ-SMMHC transcriptional networks Dr. Hyde actively mentors students interested in leukemia research and encourages inquiries about lab opportunities.

• Leukemia
• Acute Myeloid Leukemia
• Hematological Malignancies
• +5 more